Drug Approval | April 15, 2023
NS Pharma announces FDA clearance to initiate phase II study for an Exon 44 skipping candidate
Study efficacy measures will include the expression of dystrophin protein and motor function.
Study efficacy measures will include the expression of dystrophin protein and motor function.
Subscribe To Our Newsletter & Stay Updated